Over 26 million people worldwide are struggling with opioid use disorder, with more than 100,000 deaths occurring every year from overdoses. These numbers have steadily increased in the last 20 years, with the last two years seeing a drastic rise in opioid-related deaths. A major problem contributing to the opioid crisis is people can experience severe withdrawal symptoms when they attempt to stop their opioid use. The debilitating symptoms of opioid withdrawal can affect anyone on long-term opioid drugs, not just those with opioid use disorder. Having safe and effective interventions that reduce withdrawal can break the cycle of opioid use.
Researchers out of the Hotchkiss Brain Institute in the Cumming School of Medicine at the University of Calgary have discovered a potential treatment to help those struggling with opioid use. Probenecid, a Health Canada and FDA-approved drug for gout, has shown potential in alleviating opioid withdrawal symptoms, and is entering phase 2 academic clinical trials.
Join our leading scientist Dr. Tuan Trang and other scientific, medical and mental health and addictions experts for this community-run webinar with the Hotchkiss Brain Institute discussing the potential of this research, what this means for communities worldwide, and plans to fuel the development of the science from bench to bedside.
Friday February 18th, 2022
9:00 – 10:00 am
Via Zoom Webinar – register here
For any questions about the event, contact: email@example.com